

Henry M Dunnenberger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5368379/publications.pdf>

Version: 2024-02-01

39
papers

3,900
citations

331259

21
h-index

344852

36
g-index

41
all docs

41
docs citations

41
times ranked

3874
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 376-382.	2.3	586
2	Clinical pharmacogenetics implementation consortium guideline (CPIC) for <i>CYP2D6</i> and <i>CYP2C19</i> genotypes and dosing of tricyclic antidepressants: 2016 update. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 37-44.	2.3	450
3	Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers. <i>Annual Review of Pharmacology and Toxicology</i> , 2015, 55, 89-106.	4.2	442
4	Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). <i>Genetics in Medicine</i> , 2017, 19, 215-223.	1.1	410
5	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 321-326.	2.3	325
6	Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Carbamazepine Dosing. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 324-328.	2.3	237
7	Clinical Pharmacogenetics Implementation Consortium Guideline for <i>CYP2D6</i> , <i>OPRM1</i> , and <i>COMT</i> Genotypes and Select Opioid Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 888-896.	2.3	212
8	Clinical Pharmacogenetics Implementation Consortium Guideline for <i>HLA</i> Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 574-581.	2.3	211
9	PharmVar GeneFocus: <i>CYP2D6</i> . <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 154-170.	2.3	156
10	PharmGKB summary. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 679-686.	0.7	120
11	Integrating pharmacogenomics into electronic health records with clinical decision support. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 1967-1976.	0.5	118
12	Implementation of a multidisciplinary pharmacogenomics clinic in a community health system. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 1956-1966.	0.5	101
13	Developing knowledge resources to support precision medicine: principles from the Clinical Pharmacogenetics Implementation Consortium (CPIC). <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2016, 23, 796-801.	2.2	83
14	Primary care physician experiences with integrated pharmacogenomic testing in a community health system. <i>Personalized Medicine</i> , 2017, 14, 389-400.	0.8	49
15	The 2016 ACCP Pharmacotherapy Didactic Curriculum Toolkit. <i>Pharmacotherapy</i> , 2016, 36, e189-e194.	1.2	47
16	Precision pharmacotherapy: Integrating pharmacogenomics into clinical pharmacy practice. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2019, 2, 303-313.	0.5	45
17	Patient perspectives following pharmacogenomics results disclosure in an integrated health system. <i>Pharmacogenomics</i> , 2018, 19, 321-331.	0.6	38
18	Pharmacogenomics Implementation: Considerations for Selecting a Reference Laboratory. <i>Pharmacotherapy</i> , 2017, 37, 1014-1022.	1.2	32

#	ARTICLE	IF	CITATIONS
19	Moving Pharmacogenetics Into Practice: It's All About the Evidence!. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 649-661.	2.3	31
20	Pharmacogenomic Clinical Decision Support: A Review, How to Guide, and Future Vision. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 44-57.	2.3	25
21	Value of Supportive Care Pharmacogenomics in Oncology Practice. <i>Oncologist</i> , 2018, 23, 956-964.	1.9	24
22	Primary Care Physician Experiences with Integrated Population-Scale Genetic Testing: A Mixed-Methods Assessment. <i>Journal of Personalized Medicine</i> , 2020, 10, 165.	1.1	22
23	Implementing Primary Care Mediated Population Genetic Screening Within an Integrated Health System. <i>Journal of the American Board of Family Medicine</i> , 2021, 34, 861-865.	0.8	20
24	Patient-Reported Outcomes and Experiences with Population Genetic Testing Offered Through a Primary Care Network. <i>Genetic Testing and Molecular Biomarkers</i> , 2021, 25, 152-160.	0.3	19
25	Primary care physician experiences utilizing a family health history tool with electronic health record-integrated clinical decision support: an implementation process assessment. <i>Journal of Community Genetics</i> , 2020, 11, 339-350.	0.5	16
26	Considerations for the Utility of the CPIC Guideline for CYP2D6 Genotype and Codeine Therapy. <i>Clinical Chemistry</i> , 2015, 61, 775-776.	1.5	13
27	A Case of Severe, Nilotinib-Induced Liver Injury. <i>ACG Case Reports Journal</i> , 2019, 6, e00003.	0.2	11
28	Flype: Software for enabling personalized medicine. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2021, 187, 37-47.	0.7	8
29	Pharmacogenomic Clinical Decision Support: A Scoping Review. <i>Clinical Pharmacology and Therapeutics</i> , 2023, 113, 803-815.	2.3	8
30	Solvent-Free C-Benzoylation and N-Benzoylation Reactions Using Microwave Heating. <i>Synthetic Communications</i> , 2011, 41, 2888-2898.	1.1	7
31	Synthesis of major pharmacogenomics pretest counseling themes: a multisite comparison. <i>Pharmacogenomics</i> , 2021, 22, 165-176.	0.6	7
32	Development and Implementation of In-House Pharmacogenomic Testing Program at a Major Academic Health System. <i>Frontiers in Genetics</i> , 2021, 12, 712602.	1.1	6
33	Variant Interpretation in Current Pharmacogenetic Testing. <i>Journal of Personalized Medicine</i> , 2020, 10, 204.	1.1	5
34	Value of Personalized Medicine. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 612.	3.8	4
35	The Contribution of Pharmacogenetic Drug Interactions to 90-Day Hospital Readmissions: Preliminary Results from a Real-World Healthcare System. <i>Journal of Personalized Medicine</i> , 2021, 11, 1242.	1.1	4
36	The pharmacist's responsibility to ensure appropriate use of direct-to-consumer genetic testing. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2021, 4, 652-658.	0.5	4

#	ARTICLE	IF	CITATIONS
37	Pharmacogenomics Education and Clinical Practice Guidelines. , 2019, , 395-414.		2
38	Genetic Contributions and Personalized Medicine. , 2018, , 3-16.		1
39	Effect Modification by Social Determinants of Pharmacogenetic Medication Interactions on 90-Day Hospital Readmissions within an Integrated U.S. Healthcare System. Journal of Personalized Medicine, 2022, 12, 1145.	1.1	1